Latest news and press releases about Fortrea Holdings Inc. (FTRE): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development.
Price
| Price | $19.97 |
| Market Cap | $1.9B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.46 |
| EV / EBITDA | 31.35 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -15.53% |
| Return on Invested Capital | 0.62% |
| Return on Assets | -3.14% |
| Gross Margin | 17.11% |
| Operating Margin | 0.41% |
| Net Margin | -3.18% |
Related companies: ANAB · AVBP · BBOT · EYPT · KURA · MRVI · PHAT
Explore sector: Healthcare · Biotechnology
More sections of FTRE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks